DFIB Cardiac Science (MM)

Cardiac Science Receives Canadian Regulatory Approval to Market Fully-Automatic Public-Access Defibrillator Fully-Automatic Powerheart(R) AED Only Requires Attachment to Victim to Provide Lifesaving Treatment IRVINE, Calif., May 20 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of live-saving public-access defibrillators (AEDs), today announced that it has been granted approval by the Canadian Regulatory Agency, Health Canada Therapeutic Products Directorate (HCTPD), to begin marketing its patented fully-automatic Powerheart(R) public-access AED in Canada. The Powerheart G3-Automatic which was previously 510(k) approved for sale in the United States by the U.S. Food and Drug Administration (FDA) in 2004, is the first fully-automatic AED in the Powerheart product line and is designed specifically for use in public places, workplace settings and in-home use by consumers. In order to use the G3-Automatic, a rescuer need only listen to the Powerheart's detailed voice instructions explaining how to attach the device to the heart attack victim. There are no buttons to push or additional action required since the Powerheart analyzes the patient's condition to detect a life-threatening heart rhythm and, if appropriate, automatically delivers a potentially lifesaving defibrillation shock(s) to restore the heart to a normal rhythm. Cardiac Science Chief Marketing Officer Michael Gioffredi said, "Since its launch in the U.S. market last year, the Powerheart G3-Automatic has been our most popular AED for the public-access marketplace where ease of use and self-testing capabilities have been the primary drivers fueling customer acceptance." Gioffredi continued, "We are currently shipping our semi-automatic Powerheart G3 AED product to our distribution partners in Canada, and this regulatory clearance expands the marketing opportunities for Cardiac Science, providing those distributors with an AED product that is easily differentiated from our competitors." According to the Canadian Heart and Stroke Foundation, cardiovascular disease accounts for more deaths in Canada than any other disease. About Health Canada, Therapeutic Products Directorate (HCTPD) HCTPD, the Canadian medical products regulatory authority, acts independently of the U.S. Food and Drug Administration. FDA approval alone does not qualify a medical device for importation into Canada. Before medical devices can be legally supplied in Canada, medical devices are subject to rigorous review, and manufacturers are obligated to provide evidence to establish quality, safety and efficacy of their device, as well as the standard of manufacture of the goods, for review by HCTPD, prior to approval. About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automatic public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company makes the Powerheart(R) CRM(R), the only FDA-cleared therapeutic bedside patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call (949) 797-3800. This press release includes forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Cardiac Science has based these forward-looking statements on the current expectations, assumptions, estimates and projections. While Cardiac Science believes Canadian HCTPD approval will lead to future purchases of AEDs, these expectations, assumptions, estimates and projections, while reasonable, are forward-looking statements and are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. Certain factors, including those discussed in Cardiac Sciences' Annual Report on Form 10-K for the year ended December 31, 2004, under the heading "Risk Factors," may cause the actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. Contact: Matt Clawson (Investors) Michael D. Gioffredi Allen & Caron Inc Chief Marketing Officer (949) 474-4300 Cardiac Science, Inc. (949) 797-3800 DATASOURCE: Cardiac Science, Inc. CONTACT: Investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300, , for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright